Displaying archives for 2012 December:

You are here Home › News › SF Native Runs Cross-Country to Raise Lung Cancer Awareness › SF Native Runs Cross-Country to Raise Lung Cancer Awareness

lung_run_web
Posted by Samantha Powell on December 12th, 2012 | No comments

Friend was inspired by Cal athlete’s lung cancer battle By Brittany Harrison/ Contributing Writer What can you do with your lungs? A lot. That’s what my sister, Kelcey Harrison, set out to prove when she left New York City on July 30 to run across the country to San Francisco. She completed the journey, known […]

Kelcey Harrison completes nationwide ‘lung run’

espnw_r_kelcey-harrison_mb_576
Posted by Samantha Powell on December 11th, 2012 | No comments

Dec 11, 2012 2:19 PM ET | By Sarah Spain A couple of Saturdays ago, while you were watching college football or out buying a Christmas tree, 24-year-old Kelcey Harrison was running the last 20 miles of a 3,500-mile “jog” from Times Square to her hometown of San Francisco. Harrison, who graduated from Harvard, where […]

Denosumab extended survival in lung cancer with bone metastases

Posted by Samantha Powell on December 6th, 2012 | No comments

Denosumab extended survival in lung cancer with bone metastases   By: Delicia Honen Yard The monoclonal antibody denosumab, which reduces the incidence of skeletal-related events in persons with bone metastases from solid tumors, was recently shown to improve overall survival in persons with metastatic lung cancer more effectively than did zoledronic acid. In the randomized […]

Selumetinib plus docetaxel shows KRAS-mutant NSCLC potential

Posted by Samantha Powell on December 3rd, 2012 | No comments

Selumetinib plus docetaxel shows KRAS-mutant NSCLC potential   By Lynda Williams, Senior medwireNews Reporter The addition of selumetinib to docetaxel therapy may boost the survival of patients with KRAS-mutant non-small-cell lung cancer (NSCLC), suggest study findings published in The Lancet Oncology. The median overall survival of patients with stage IIIB-IV disease given selumetinib plus docetaxel […]

Anticancer Drug Benefits Persist with Local Treatment

Posted by Samantha Powell on December 1st, 2012 | No comments

Anticancer Drug Benefits Persist with Local Treatment By Nancy Walsh, Staff Writer, MedPage Today Local ablation may allow patients with non-small cell lung cancer who experience limited progression on tyrosine kinase inhibitors to continue to derive benefit from the drugs, a small, single-center, retrospective study suggested. Among 25 patients with oncogene-associated NSCLC whose progressive disease […]